Retatrutide 16mg (4 PENS)

BUY Retatrutide 16mg

 

Retatrutide (LY3437943) is an investigational, once-weekly injectable peptide developed by Eli Lilly for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). The 16mg dose, not yet studied in published phase 2 trials, is a hypothetical high-dose extension based on ongoing phase 3 TRIUMPH trials. Administered via subcutaneous injection, it’s not FDA-approved and unavailable outside clinical trials.

 

retatrutide peptide

 

Mechanisms of Action
Retatrutide, a triple agonist, targets GLP-1, GIP, and glucagon receptors. GLP-1 suppresses appetite and slows gastric emptying, GIP enhances insulin sensitivity and fat metabolism, and glucagon increases energy expenditure by promoting fat burning. This multi-receptor approach, with a ~6-day half-life, outperforms dual agonists like tirzepatide. Phase 2 data at 12mg showed 24.2% weight loss over 48 weeks, suggesting 16mg may yield even greater efficacy.

 

retatrutide dosing​

 

 

 

Weight Loss: At 12mg, achieved 24.2% (58 lbs) mean weight loss; 16mg may approach 25–30% based on dose-dependent trends.

 

Blood Sugar Control: Reduces HbA1c by ~2%, with 82% of type 2 diabetes patients reaching <6.5% at 12mg.

 

Liver Health: Reduced liver fat by 82.4% at 12mg in MASLD patients, likely enhanced at 16mg.

 

retatrutide dosage

 

 

Cardiometabolic Health: Improves blood pressure, triglycerides, and LDL cholesterol.
Phase 2 trials suggest no weight plateau at 48 weeks, indicating further potential.

Dosage and Administration
Hypothetical 16mg dosing would follow titration: 2mg weekly for 4 weeks, escalating to 4mg, 8mg, 12mg, then 16mg, with 4 weeks per step. Inject into the abdomen, thigh, or upper arm, rotating sites. Administer any time of day; store vials refrigerated (36–46°F). Dosing awaits phase 3 confirmation (NCT04881760).

 

retatrutide dosage chart

 

Safety and Side Effects
Common side effects include nausea, vomiting, and diarrhea (20–40%), peaking during escalation. At 12mg, 7% reported cutaneous hyperesthesia; 16mg may increase this risk. Serious risks include transient heart rate increases and rare pancreatitis. Not suitable for thyroid cancer history or severe liver/renal issues.

 

retatrutide how to get

 

Legal Status
Not FDA-approved; available only in clinical trials. Banned by WADA. Obtain via research protocols.